<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">23548622</PMID>
<DateCompleted>
<Year>2013</Year>
<Month>06</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1552-5783</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>54</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2013</Year>
<Month>Apr</Month>
<Day>26</Day>
</PubDate>
</JournalIssue>
<Title>Investigative ophthalmology &amp; visual science</Title>
<ISOAbbreviation>Invest. Ophthalmol. Vis. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.</ArticleTitle>
<Pagination>
<MedlinePgn>2941-50</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1167/iovs.13-11650</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To investigate the safety and effects of subconjunctival sirolimus, an mTOR inhibitor and immunosuppressive agent, for the treatment of geographic atrophy (GA).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">The study was a single-center, open-label phase II trial, enrolling 11 participants with bilateral GA; eight participants completed 24 months of follow-up. Sirolimus (440 μg) was administered every 3 months as a subconjunctival injection in only one randomly assigned eye in each participant for 24 months. Fellow eyes served as untreated controls. The primary efficacy outcome measure was the change in the total GA area at 24 months. Secondary outcomes included changes in visual acuity, macular sensitivity, central retinal thickness, and total drusen area.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The study drug was well tolerated with few symptoms and related adverse events. Study treatment in study eyes was not associated with structural or functional benefits relative to the control fellow eyes. At month 24, mean GA area increased by 54.5% and 39.7% in study and fellow eyes, respectively (P = 0.41), whereas mean visual acuity decreased by 21.0 letters and 3.0 letters in study and fellow eyes, respectively (P = 0.03). Substantial differences in mean changes in drusen area, central retinal thickness, and macular sensitivity were not detected for all analysis time points up to 24 months.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Repeated subconjunctival sirolimus was well-tolerated in patients with GA, although no positive anatomic or functional effects were identified. Subconjunctival sirolimus may not be beneficial in the prevention of GA progression, and may potentially be associated with effects detrimental to visual acuity. (ClinicalTrials.gov number, NCT00766649.).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Wong</LastName>
<ForeName>Wai T</ForeName>
<Initials>WT</Initials>
<AffiliationInfo>
<Affiliation>Unit on Neuron–Glia Interactions in Retinal Disease, Building 6, Room 215, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. wongw@nei.nih.gov</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Dresner</LastName>
<ForeName>Samuel</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Forooghian</LastName>
<ForeName>Farzin</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Glaser</LastName>
<ForeName>Tanya</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Doss</LastName>
<ForeName>Lauren</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Zhou</LastName>
<ForeName>Mei</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cunningham</LastName>
<ForeName>Denise</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shimel</LastName>
<ForeName>Katherine</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Harrington</LastName>
<ForeName>Molly</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hammel</LastName>
<ForeName>Keri</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Cukras</LastName>
<ForeName>Catherine A</ForeName>
<Initials>CA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ferris</LastName>
<ForeName>Frederick L</ForeName>
<Initials>FL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chew</LastName>
<ForeName>Emily Y</ForeName>
<Initials>EY</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y">
<DataBank>
<DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList>
<AccessionNumber>NCT00766649</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList>
<PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>04</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Invest Ophthalmol Vis Sci</MedlineTA>
<NlmUniqueID>7703701</NlmUniqueID>
<ISSNLinking>0146-0404</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>W36ZG6FT64</RegistryNumber>
<NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057092">Geographic Atrophy</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007166">Immunosuppressive Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D056965">Injections, Intraocular</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D009887">Ophthalmoscopy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D010781">Photography</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012160">Retina</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015593">Retinal Drusen</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D020123">Sirolimus</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014792">Visual Acuity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058609">Visual Field Tests</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>4</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>4</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2013</Year>
<Month>6</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23548622</ArticleId>
<ArticleId IdType="pii">iovs.13-11650</ArticleId>
<ArticleId IdType="doi">10.1167/iovs.13-11650</ArticleId>
<ArticleId IdType="pmc">PMC3638660</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Invasive Cardiol. 2012 Jun;24(6):261-2</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22684378</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Surg Res. 2007 Mar;138(1):37-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17109887</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transplant Proc. 2003 May;35(3 Suppl):18S-24S</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12742464</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Eye Res. 2003 Apr;76(4):463-71</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12634111</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Health Syst Pharm. 2004 Mar 1;61(5):449-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15018222</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1994 Jun 30;369(6483):756-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8008069</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Ophthalmol. 2009 Sep;127(9):1168-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19752426</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging (Albany NY). 2011 Apr;3(4):346-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21483039</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Aging Cell. 2012 Aug;11(4):675-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22587563</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>FASEB J. 2005 Feb;19(2):246-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15546959</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Biochem. 1998 Jul;31(5):335-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9721431</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurotoxicology. 2011 Jan;32(1):50-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21075140</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell. 2006 Apr 21;22(2):159-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16603397</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Ophthalmol. 2010 May;21(3):190-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20216419</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19812304</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neuron. 2012 Jul 12;75(1):26-39</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22794258</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Graefes Arch Clin Exp Ophthalmol. 2002 Feb;240(2):73-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11933894</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Epidemiol. 2012 Sep 1;176(5):361-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22869612</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Graefes Arch Clin Exp Ophthalmol. 2011 Nov;249(11):1627-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21567211</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA Ophthalmol. 2013 Jan;131(1):110-1</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23307222</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Neurosci. 2010 Jan 20;30(3):1166-75</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20089925</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2010;5(9). pii: e12845. doi: 10.1371/journal.pone.0012845</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20862226</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Prog Neurobiol. 2012 Nov;99(2):128-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22980037</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eye (Lond). 1988;2 ( Pt 5):552-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2476333</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Physiol Renal Physiol. 2011 Jan;300(1):F236-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20943770</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Ophthalmol. 2011 May;26(3):167-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21609230</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Inflamm Res. 2000 Jan;49(1):20-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10778917</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4137-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18487363</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Aspects Med. 2012 Aug;33(4):487-509</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22705444</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2004 Feb 1;10(3):1013-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14871980</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Ophthalmol. 2005 Jun;89(6):666-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15923497</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Am Coll Cardiol. 2007 Nov 27;50(22):2111-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18036446</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Exp Eye Res. 2011 Oct;93(4):413-23</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21684273</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurosci Lett. 2012 Dec 7;531(2):74-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23127854</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Vet Pharmacol Ther. 2008 Dec;31(6):511-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19000272</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5314-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20445122</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ophthalmology. 2012 Jan;119(1):124-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22115710</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Cycle. 2009 Apr 1;8(7):1026-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19270529</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Epidemiol. 2011 Jun 15;173(12):1365-79</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21576320</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Invest Ophthalmol Vis Sci. 2010 Feb;51(2):637-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19797219</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Retina. 2007 Feb;27(2):204-10</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17290203</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Ophthalmol. 2011 May;22(3):190-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21427574</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Ophthalmol. 2012 Jun;153(6):1038-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22465364</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Semin Immunopathol. 2008 Apr;30(2):97-110</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18299834</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Ophthalmol. 2012 Jun;153(6):1116-24.e1</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22321802</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6241-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21444807</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1994 Jul 15;78(1):35-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7518356</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Ocul Pharmacol Ther. 2012 Oct;28(5):507-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22662868</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2012;7(5):e36589</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22574188</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2012 Apr 13;149(2):274-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22500797</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Retina. 2010 Nov-Dec;30(10):1579-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20847709</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2006 Aug;10(2):159-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16904613</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ophthalmology. 2011 Apr;118(4):679-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21035861</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ophthalmology. 2003 Feb;110(2):392-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12578786</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Neurochem Res. 2013 Jan;38(1):201-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23117422</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Ophthalmic Inflamm Infect. 2010 Dec 07;1(1):29-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21475659</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Invest Ophthalmol Vis Sci. 2011 Feb;52(2):1119-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20926818</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Brain Res. 2007 Sep 7;1168:97-105</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17706618</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 2011 Jan;121(1):369-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21135502</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Mol Genet. 2006 Sep 15;15(18):2784-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16905558</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Retina. 2000;20(2):162-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10783949</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2012 Mar 30;335(6076):1638-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22461615</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6131-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20574018</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transplant Proc. 2003 May;35(3 Suppl):7S-14S</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12742462</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ophthalmology. 1999 Sep;106(9):1768-79</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10485549</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arch Ophthalmol. 2005 Nov;123(11):1484-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16286610</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am Heart J. 2012 Jan;163(1):104-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22172443</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Prog Retin Eye Res. 2001 May;20(3):385-414</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11286898</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Retina. 2013 Mar;33(3):498-507</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23023528</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>